Understanding the Impact of Calcineurin Inhibitors on T Cell Regulation: Mechanisms and Clinical Implications.

Calcineurin inhibitors (CNIs) are key in immunosuppressive therapy for organ transplantation and autoimmune diseases by modulating T cell activation. This review details how CNIs inhibit T cell receptor signaling, cytokine production, and T cell differentiation by binding to intracellular proteins, thus preventing the activation of NFAT, a critical transcription factor. The clinical benefits of CNIs include preventing graft rejection and controlling autoimmune responses, but they also have significant side effects such as nephrotoxicity, neurotoxicity, hypertension, hyperlipidemia, and increased risk of infections and malignancies. Optimizing CNI use involves developing safer versions, personalizing regimens, and combining therapies to lower doses and reduce side effects. Understanding CNIs' interactions with T cells can improve therapy outcomes and guide the creation of targeted treatments. Effective patient monitoring and management are essential to mitigate toxicities. Future research should focus on CNIs' pharmacodynamics and pharmacokinetics in developing next-generation immunosuppressants, and personalized and combination therapies to enhance safety and efficacy, ultimately improving patient outcomes and quality of life.